Impact of Aging on Cytokine Production by Innate Immune Cells (Cytokinage)

To Investigate the Impact of Aging on Cytokine and Chemokine Production by Peripheral Blood Immune Cells

The main goal of this study is to investigate the impact of aging on the responsiveness of peripheral blood immune cells. To this aim, the investigators will take advantage of a recently described syringe-based assay system that can reproducibly assess induced, innate or adaptive immune responses. Briefly, a total of 50 healthy volunteers will participate to this study: 25 will be older than 18 and younger than 30, and 25 will be older than 55. A total of 14 ml of blood will be drawn including 5 X 1 ml in TruCulture™ tubes containing poly(I:C), R-848, LPS, CpG, or no stimulus, respectively. After 22 hours of incubation at 37°C, cellular supernatants will assessed for levels of 10 different chemokines using a MesoScaleDiscovery multiplexing platform.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Other: Healthy Volunteers

• Study Type: Interventional
• Enrollment (Actual): 50
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Alpes-Maritimes
    • Nice, Alpes-Maritimes, France, 06200
      • CHU de Nice, CRC, Hôpital de l'Archet 151 route de saint-antoine de ginestière

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• volunteers will be invited to settle an appointment with the Nice University Hospital (CHU de Nice) Research Clinical Center (CRC).
• being between 18 and 30 year-old (group Y) or being older than 55 year-old (group O),
• ability to understand and speak French,
• being registered at the Social Security,
• acceptance to be serologically tested for HIV and HVC,
• considered healthy based on both past medical records and the clinical examination performed at the inclusion visit,
• exhibiting a body mass index (body mass divided by the square of their height) comprised between 18.5 and 30.0 kg/m2.

Exclusion Criteria:

• having participated to a drug clinical trial since less than 3 months,
• having traveled to a tropical or a sub-tropical country over the past 3 months,
• being pregnant or a lactating mother (for women),
• having performed intensive physical exercise over the past 12 hours,
• following a specific diet for medical reasons,
• over-drinking, i.e. more that 50 g of pure alcohol every day,
• having taken an immuno-suppressive or immuno-modulatory drug over the past two weeks, or for at least 14 consecutive days over the past 6 months,
• having been vaccinated over the past 3 months,
• declaring not being on an empty stomach for less than 12 hours,
• having received a blood transfusion or intravenous immunoglobulins over the past 3 months,
• declaring being HIV- or HVC- positive,
• having suffered from an infection since less than 3 weeks,
• exhibiting a positive urine pregnancy test at the inclusion visit,
• suffering from a severe/chronic/relapsing pathology, i.e. inflammatory bowel disease, psoriasis, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, type I or type II diabetes, Parkinson's disease, and (p) having been diagnosed with a cancer and not being in a remitting period for less than 5 years.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Healthy Volunteers; A catheter will be introduced in the arm vein and 14 ml of blood will be drawn in one 4 ml dry tube, one 5 ml heparinized tube for cell count and 5 1 ml TruCulture tubes.	Other: Healthy Volunteers; A catheter will be introduced in the arm vein and 14 ml of blood will be drawn in one 4 ml dry tube, one 5 ml heparinized tube for cell count and 5 1 ml TruCulture tubes.; Other Names: blood test

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
CCL2 levels	Compare CCL2 levels in the supernatants of poly(I :C)-stimulated whole blood cells between volunteers aged from 18 to 30 years and volunteers older than 55	at first day

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Other CCL levels	Compare CXCL8 (IL-8) levels in the supernatants of poly(I :C)-stimulated whole blood cells between volunteers aged from 18 to 30 years and volunteers older than 55	at first day

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire de Nice
• Investigators: Principal Investigator: passeron thierry, PhD, CHU de Nice, Service de Dermatologie

Study record dates

Study Major Dates

• Study Start (Actual): February 1, 2016
• Primary Completion (Actual): February 1, 2017
• Study Completion (Actual): June 1, 2018

Study Registration Dates

• First Submitted: November 30, 2015
• First Submitted That Met QC Criteria: January 20, 2016
• First Posted (Estimate): January 21, 2016

Study Record Updates

• Last Update Posted (Actual): July 23, 2018
• Last Update Submitted That Met QC Criteria: July 20, 2018
• Last Verified: February 1, 2018

More Information

Terms related to this study

• Keywords: Volunteers; M01.774.500
• Other Study ID Numbers: 15-PP-07

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO